Unobstructed Biliary Tract Dilatation in a Patient With Breast Carcinoma and Dermatomyositis: A New Paraneoplastic Manifestation?

Katsinelos, Panagiotis; Dimiropoulos, S.; Pirpilidis, Ioannis; Christodoulou, Kirakos; Xiarchos, Panagiotis; Zisis, A; Nikos, Eugenidis

doi:10.1111/j.1572-0241.1999.03383.x

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of case reports detailed malignant disease occurring with DM [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39]. Also represented were reports regarding malignancy associated with amyopathic DM [40][41][42][43], PM [44,45], inclusion body myositis [46], and DM/inclusion body myositis overlap [47].…”

Section: Case Reportsmentioning

confidence: 99%

Malignancy in patients with inflammatory myopathy

Buchbinder

Hill

2002

Curr Rheumatol Rep

View full text Add to dashboard Cite

The most recent evidence from population-based cohort studies confirms the association between malignancy and dermatomyositis and polymyositis. These studies show an even stronger association between polymyositis and malignancy than previous studies, suggesting less misclassification. This is particularly true of one study that used pathologic criteria to distinguish between myositis subtypes. Recent data also confirm that the association for dermatomyositis and polymyositis is not purely caused by diagnostic suspicion or surveillance bias. More data are still required to determine individual cancer risks, although it appears that ovarian and lung cancer are associated with dermatomyositis while lung cancer and non-Hodgkin's lymphoma are associated with polymyositis. An association between malignant disease and inclusion body myositis has also been verified for the first time. Of interest, too, is the increasing number of reports documenting cases in which the clinical course of the myositis mirrors that of the cancer, supporting the notion that in some instances, myositis is a paraneoplastic disorder.

show abstract

Section: Case Reportsmentioning

confidence: 99%

Malignancy in patients with inflammatory myopathy

Buchbinder

Hill

2002

Curr Rheumatol Rep

View full text Add to dashboard Cite

show abstract

“…The median time to diagnosis of breast cancer from presentation with dm was 1 month (range: 29-36 months). Most patients were diagnosed with cancer before they were diagnosed with dm; only 6 of the 25 (24%) presented with myositis symptoms first 13,18,19 . The presence of dm was associated with late-stage tumours, 72% of the women (18 of the 25) having presented with stage iii or iv disease 9,10,[12][13][14][15][16][17][18]20 .…”

Section: Discussionmentioning

confidence: 99%

Breast Cancer and Dermatomyositis: A Case Study and Literature Review

et al. 2017

View full text Add to dashboard Cite

A 49-year-old woman presents with an extensive violaceous rash, rapidly progressive proximal muscle weakness, and dysphagia to solids, consistent with a diagnosis of dermatomyositis. Two weeks later, she palpates a mass in her left breast and is diagnosed with her2-positive metastatic invasive ductal carcinoma of the breast.There is a well-established association between dermatomyositis and malignancy. However, the specific association between breast cancer and dermatomyositis has not been well characterized. No guideline for oncologists managing these patients has been established. Recently, 3 cases of breast cancer and dermatomyositis were diagnosed at our institution. A review of the literature was pursued to characterize the association between breast cancer and dermatomyositis.A review of 178 papers identified 22 cases of breast cancer with dermatomyositis. Most patients (71%) presented with stage iii or iv breast cancer. The median time between the diagnosis of breast cancer and the onset of dermatomyositis symptoms was 1 month. Three quarters of the patients were steroid-responsive and able to taper. Half the women with follow-up data experienced a documented cancer relapse associated with a new flare of cutaneous symptoms.The presence of dermatomyositis appears to be associated with more-advanced breast cancer stage and is most commonly associated with invasive ductal carcinoma. In our review, treatment of cancer alone is insufficient to adequately control the cutaneous and myopathic manifestations of dermatomyositis, which can significantly affect quality of life. A multidisciplinary approach, including close collaboration with rheumatologists and dermatologists, is therefore important in the diagnosis and management of oncology patients with dermatomyositis.

show abstract

Unobstructed Biliary Tract Dilatation in a Patient With Breast Carcinoma and Dermatomyositis: A New Paraneoplastic Manifestation?

Cited by 2 publications

References 6 publications

Malignancy in patients with inflammatory myopathy

Malignancy in patients with inflammatory myopathy

Breast Cancer and Dermatomyositis: A Case Study and Literature Review

Contact Info

Product

Resources

About